CA3221138A1 - Placenta-mimic cosmectic composition - Google Patents
Placenta-mimic cosmectic composition Download PDFInfo
- Publication number
- CA3221138A1 CA3221138A1 CA3221138A CA3221138A CA3221138A1 CA 3221138 A1 CA3221138 A1 CA 3221138A1 CA 3221138 A CA3221138 A CA 3221138A CA 3221138 A CA3221138 A CA 3221138A CA 3221138 A1 CA3221138 A1 CA 3221138A1
- Authority
- CA
- Canada
- Prior art keywords
- placenta
- composition
- skin
- mimic
- cosmetic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 239000002537 cosmetic Substances 0.000 claims abstract description 48
- 230000006872 improvement Effects 0.000 claims abstract description 48
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims abstract description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 26
- 229940088594 vitamin Drugs 0.000 claims abstract description 23
- 229930003231 vitamin Natural products 0.000 claims abstract description 23
- 235000013343 vitamin Nutrition 0.000 claims abstract description 23
- 239000011782 vitamin Substances 0.000 claims abstract description 23
- 230000037303 wrinkles Effects 0.000 claims abstract description 23
- 150000001413 amino acids Chemical class 0.000 claims abstract description 22
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 22
- 230000002087 whitening effect Effects 0.000 claims abstract description 22
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 claims description 26
- 229940024606 amino acid Drugs 0.000 claims description 21
- 235000001014 amino acid Nutrition 0.000 claims description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 4
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- QMIFIFIYYPUVNU-ACMTZBLWSA-L copper (2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-imidazol-1-id-4-ylpropanoyl]amino]hexanoate Chemical compound [Cu+2].NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=C[N-]C=N1 QMIFIFIYYPUVNU-ACMTZBLWSA-L 0.000 claims description 4
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 claims description 4
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229940055726 pantothenic acid Drugs 0.000 claims description 4
- 235000019161 pantothenic acid Nutrition 0.000 claims description 4
- 239000011713 pantothenic acid Substances 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 229940068988 potassium aspartate Drugs 0.000 claims description 4
- 235000008160 pyridoxine Nutrition 0.000 claims description 4
- 239000011677 pyridoxine Substances 0.000 claims description 4
- 229960002477 riboflavin Drugs 0.000 claims description 4
- 235000019192 riboflavin Nutrition 0.000 claims description 4
- 239000002151 riboflavin Substances 0.000 claims description 4
- 229940073490 sodium glutamate Drugs 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- 235000019157 thiamine Nutrition 0.000 claims description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 4
- 239000011721 thiamine Substances 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960002104 cyanocobalamin Drugs 0.000 claims description 3
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 3
- 239000011666 cyanocobalamin Substances 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 235000004554 glutamine Nutrition 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 235000013930 proline Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 39
- 210000002826 placenta Anatomy 0.000 abstract description 21
- 239000004615 ingredient Substances 0.000 abstract description 3
- 239000007995 HEPES buffer Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 71
- 230000000052 comparative effect Effects 0.000 description 52
- 238000004519 manufacturing process Methods 0.000 description 16
- 229920002674 hyaluronan Polymers 0.000 description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 229960003160 hyaluronic acid Drugs 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 230000036570 collagen biosynthesis Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000008099 melanin synthesis Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 230000037394 skin elasticity Effects 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000036564 melanin content Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- -1 PDRN Chemical compound 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 101100243951 Caenorhabditis elegans pie-1 gene Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
Abstract
The present invention provides a placenta-mimic cosmetic composition which shows excellent skin improvement effects such as whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing by, instead of directly using the placenta containing ingredients that have legal, ethical, and safety issues, adding HEPES to PDRN, which is a major component of the placenta, and adding peptides, amino acids, or vitamins to same to recombine.
Description
[DESCRI PTI ON]
[Invention Title]
PLACENTA-MIMIC COSMETIC COMPOSITION
[Technical Field]
The present invention relates to a placenta-mimic cosmetic composition that shows excellent skin improvement effects such as whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing by, instead of directly using the placenta containing ingredients that have legal, ethical, and safety issues, adding HEPES to PDRN, which is a major component of the placenta, and adding peptides, amino acids, or vitamins to the same to recombine.
[Background Art]
Skin is a tissue that covers the outermost part of the body, and always is in contact with the external environment and protects the human body from harmful factors. In addition, since the skin is a visually recognized area, it also determines how beautiful the body is. As signs of aging such as wrinkles, pigmentation, and inflammation accumulate on the skin, its aesthetic value decreases, and thus, there has always been a consumer need for solutions that can prevent or improve these signs.
The placenta is an organ that develops in the uterus of pregnant mammals. The placenta connects the fetus and the mother's uterine wall and is in charge of functions such as supply of nutrients, gas exchange, and excretion of waste products, enabling the fetus to survive and grow within the mother's body and playing a role in protecting the fetus. Such a placenta includes essential amino acids, nucleic acid components such as DNA and RNA, cytokines, growth factors, and the like, and is known to have effective effects such as whitening, wrinkle improvement, immunity enhancement, fatigue recovery, and the like. In herbal medicine, the placenta is called J ahageo and has been used to treat cases such as lack of Qi and blood and thinness due to illness, cases of blemishes on the face and darkened skin due to consumptive diseases, and the like.
Accordingly, prior literature such as "Cosmetic composition using porcine placenta, human placenta extract or hydrolyzed extract (Korean Patent Laid-Open Publication No. 10-2009-000244)", and "Cosmetic composition reconstituted with human placenta-derived growth factors and cytokines (Korean Registered Patent No. 10-1289062)" is known. However, when the placenta is included in cosmetics, it is undesirable from a safety perspective because it may include components that cause viral infection or immune rejection. Moreover, since the placenta is an animal raw material, consumers may feel aversion to cosmetics that include it.
In addition, growth factors and cytokines are components that currently cannot be used in the field of cosmetics.
That is, the related art has limitations in implementing cosmetics that fully show the skin improvement effects of the placenta.
Therefore, there is a need for technology that can solve the safety, ethical, and legal issues of the placenta while maintaining and developing the excellent skin improvement efficacy of the placenta.
[Related Art Literature]
[Patent Documents]
(Patent Document 001) Korean Patent Laid-Open Publication No. 10-2009-0002444 (Patent Document 002) Korean Registered Patent No. 10-1289062 [Disclosure]
[Technical Problem]
The present invention is directed to providing a placenta-mimic cosmetic composition having safety and effectiveness.
The present invention is also directed to providing a use of a placenta-mimic composition for manufacturing cosmetics, pharmaceutical preparations or food for skin whitening.
The present invention is also directed to providing a use of a placenta-mimic composition for manufacturing cosmetics, pharmaceutical preparations or food for improving skin elasticity.
The present invention is also directed to providing a use of a placenta-mimic composition for manufacturing cosmetics, pharmaceutical preparations or food for improving skin wrinkles.
The present invention is also directed to providing a use of a placenta-mimic composition for manufacturing cosmetics, pharmaceutical preparations or food for skin moisturizing.
The present invention is also directed to providing a use of a placenta-mimic composition for manufacturing cosmetics, pharmaceutical preparations or food for skin soothing.
[Technical Solution]
As a means for solving the above problems, one aspect of the present invention provides a placenta-mimic composition including, as an active ingredient, Polydeoxyribonucleotide (PDRN) and Hydroxyethylpiperazine Ethane Sulfonic Acid (HEPES) which are recombined by by adding peptides, amino acids, or vitamins.
To achieve the above objective, the present invention provides a method for improving skin such as whitening, improving elasticity, reducing wrinkles, moisturizing, or soothing the skin, which includes steps by applying a placenta-mimic composition to the skin.
To achieve the above objective, the present invention provides a method for improving skin such as whitening, improving elasticity, reducing wrinkles, moisturizing, or soothing the skin, which includes steps by administering a placenta-mimic composition to a subject.
To achieve the above objective, the present invention provides a use of a placenta-mimic composition including, as an active ingredient, Polydeoxyribonucleotide (PDRN) and Hydroxyethylpiperazine Ethane Sulfonic Acid (HEPES) which are recombined by by adding peptides, amino acids, or vitamins, for manufacturing the placenta-mimic composition that shows excellent skin improvement effects such as whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing.
Hereinafter, the placenta-mimic composition according to the present invention will be described in more detail.
In the present invention, growth factors, hormones, and cytokines with legal, ethical, and safety issues are excluded.
In the related art, a cosmetic composition including a placenta extract powder hydrolyzed with a proteolytic enzyme as an active ingredient (Korean Patent Laid-Open Publication No. 10-2009-0002444) and a cosmetic composition including growth factors and cytokines extracted from the placenta as active ingredients (Korean Registered Patent No. 10-1289062) are disclosed.
However, the above related arts are aimed at extracting components which have not had their safety confirmed and are legally regulated, such as growth-promoting factors, cytokines, epithelial cell-promoting factors, and the like from the placenta or optimizing a mixing ratio for reconstituting the composition to maximize the efficacy of the components. In addition, there is a difference in purpose because there is no description of safety verification for cosmetic compositions containing the aforementioned ingredients. Furthermore, in terms of measuring skin improvement effects, the prior arts suggest only subjective results of wrinkle improvement by visual inspection, rather than through quantitative analysis using specialized equipment to assess the efficacy of active ingredients for skin improvement, such as skin whitening, elasticity, moisturizing, or soothing anti-inflammatory effects. Therefore, Objective results based on above standardized testing methods for are not presented in prior arts, making it difficult to assess the extent of improvement.
On the other hand, specific embodiments of present invention suggest preparation of a placenta-mimic composition, in vitro and in vivo efficacy tests by using standard test methods or specialized analysis equipment. Through the embodiments of present invention, it was confirmed that the placenta-mimic composition, as an active ingredient, could significantly improve each skin conditions and maximize the efficacy of whitening, elasticity, wrinkle, moisturizing, or skin soothing.
In a specific embodiment of the present invention, further improved effects may be achieved by recombining PDRN and HEPES by adding peptides, amino acids, and vitamins.
Specifically, in an in vitro efficacy test, it was confirmed that the skin improvement effect of inhibiting melanin production, promoting collagen biosynthesis, promoting hyaluronic acid 1() biosynthesis, or inhibiting NO production was improved in Example 2 (including PDRN, HEPES, peptides, amino acids, and vitamins) compared to Example 1 (including PDRN, and HEPES). In addition, in an in vivo efficacy test, it was confirmed that the skin wrinkle improvement, elasticity improvement, whitening, or moisturizing effect was improved in Examples 3 and 4 (cosmetic composition including Example 2) compared to Comparative Examples 6 and 7 (cosmetic composition without Example 2). Furthermore, the cosmetic composition according to the present invention may eliminate the risk of unexpected contamination, impossibility of implementation (legal regulations), and consumer reluctance by recombining PDRN and HEPES
with additional peptides, amino acids, and vitamins.
In the present invention, as the peptides, one or more combinations selected from the group consisting of yeast polypeptides, oligopeptide-1, oligopeptide-2, copper tripeptide-1, and acetyl hexapeptide-8 may be used.
In the present invention, as the amino acids, one or more selected from the group consisting of arginine, tryptophan, threonine, lysine, valine, leucine, phenylalanine, histidine, isoleucine, tyrosine, potassium aspartate, sodium glutamate, glutamine, asparagine, proline, a lanine, glycine, and serine may be used.
In the present invention, as the vitamins, one or more selected from the group consisting of biotin, folic acid, cyanocobalamin, niacinamide, pantothenic acid, pyridoxine, riboflavin, and thiamine may be used.
One aspect of the present invention provides a cosmetic composition including the placenta-mimic composition as an active ingredient.
In the present invention, when the placenta-mimic composition is applied to a cosmetic composition, whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing efficacy can be exhibited, and specifically, a skin improvement effect may be obtained by inhibiting melanin synthesis, promoting collagen synthesis, promoting hyaluronic acid synthesis, or inhibiting NO production.
In the present invention, the cosmetic composition may be in a form of a general emulsified formulation and solubilized formulation. For example, the cosmetic composition may have a formulation such as a lotion such as softening lotion, nourishing lotion, or the like, an emulsion such as facial lotion, body lotion, or the like, a cream such as nourishing cream, moisture cream, eye cream, or the like, an essence, cosmetic ointment, balm, spray, gel, pack, sunscreen, makeup base, a foundation such as liquid type, solid type, spray type, or the like, powder, a makeup remover such as cleansing cream, cleansing lotion, cleansing oil, or the like, a cleanser such as cleansing foam, soap, body wash, or the like.
In addition, the cosmetic may include, in addition to the composition of the present invention, an adjuvant commonly used in the field of cosmetology, such as a fatty substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic emulsifier, a filler, metal ion sequestering and chelating agents, a preservative, a vitamin, a blocking agent, a wetting agent, an essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent, a lipid vesicle or, any other components commonly used in cosmetics.
The cosmetic formulation may include a relatively high concentration of the composition of the present invention in a case of wash-off type cosmetics such as makeup removers, cleansers, and the like in which active ingredients stay on the skin for a short period of time. On the other hand, in a case of leave-on type cosmetics such as lotions, emulsions, creams, essence, and the like in which active ingredients stay on the skin for a long period of time, it is acceptable to include the composition of the present invention at a low concentration relative to that used in the wash-off type cosmetics. Although not limited thereto, in a specific embodiment of the present invention, the composition of the present invention may include 0.001 to 5 parts by weight of the placenta-mimic composition based on a total weight of the composition, for example, 0.001 to 0.01 parts by weight, 0.001 to 0.1 parts by weight, 0.001 to 1 part by weight, 0.001 to
[Invention Title]
PLACENTA-MIMIC COSMETIC COMPOSITION
[Technical Field]
The present invention relates to a placenta-mimic cosmetic composition that shows excellent skin improvement effects such as whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing by, instead of directly using the placenta containing ingredients that have legal, ethical, and safety issues, adding HEPES to PDRN, which is a major component of the placenta, and adding peptides, amino acids, or vitamins to the same to recombine.
[Background Art]
Skin is a tissue that covers the outermost part of the body, and always is in contact with the external environment and protects the human body from harmful factors. In addition, since the skin is a visually recognized area, it also determines how beautiful the body is. As signs of aging such as wrinkles, pigmentation, and inflammation accumulate on the skin, its aesthetic value decreases, and thus, there has always been a consumer need for solutions that can prevent or improve these signs.
The placenta is an organ that develops in the uterus of pregnant mammals. The placenta connects the fetus and the mother's uterine wall and is in charge of functions such as supply of nutrients, gas exchange, and excretion of waste products, enabling the fetus to survive and grow within the mother's body and playing a role in protecting the fetus. Such a placenta includes essential amino acids, nucleic acid components such as DNA and RNA, cytokines, growth factors, and the like, and is known to have effective effects such as whitening, wrinkle improvement, immunity enhancement, fatigue recovery, and the like. In herbal medicine, the placenta is called J ahageo and has been used to treat cases such as lack of Qi and blood and thinness due to illness, cases of blemishes on the face and darkened skin due to consumptive diseases, and the like.
Accordingly, prior literature such as "Cosmetic composition using porcine placenta, human placenta extract or hydrolyzed extract (Korean Patent Laid-Open Publication No. 10-2009-000244)", and "Cosmetic composition reconstituted with human placenta-derived growth factors and cytokines (Korean Registered Patent No. 10-1289062)" is known. However, when the placenta is included in cosmetics, it is undesirable from a safety perspective because it may include components that cause viral infection or immune rejection. Moreover, since the placenta is an animal raw material, consumers may feel aversion to cosmetics that include it.
In addition, growth factors and cytokines are components that currently cannot be used in the field of cosmetics.
That is, the related art has limitations in implementing cosmetics that fully show the skin improvement effects of the placenta.
Therefore, there is a need for technology that can solve the safety, ethical, and legal issues of the placenta while maintaining and developing the excellent skin improvement efficacy of the placenta.
[Related Art Literature]
[Patent Documents]
(Patent Document 001) Korean Patent Laid-Open Publication No. 10-2009-0002444 (Patent Document 002) Korean Registered Patent No. 10-1289062 [Disclosure]
[Technical Problem]
The present invention is directed to providing a placenta-mimic cosmetic composition having safety and effectiveness.
The present invention is also directed to providing a use of a placenta-mimic composition for manufacturing cosmetics, pharmaceutical preparations or food for skin whitening.
The present invention is also directed to providing a use of a placenta-mimic composition for manufacturing cosmetics, pharmaceutical preparations or food for improving skin elasticity.
The present invention is also directed to providing a use of a placenta-mimic composition for manufacturing cosmetics, pharmaceutical preparations or food for improving skin wrinkles.
The present invention is also directed to providing a use of a placenta-mimic composition for manufacturing cosmetics, pharmaceutical preparations or food for skin moisturizing.
The present invention is also directed to providing a use of a placenta-mimic composition for manufacturing cosmetics, pharmaceutical preparations or food for skin soothing.
[Technical Solution]
As a means for solving the above problems, one aspect of the present invention provides a placenta-mimic composition including, as an active ingredient, Polydeoxyribonucleotide (PDRN) and Hydroxyethylpiperazine Ethane Sulfonic Acid (HEPES) which are recombined by by adding peptides, amino acids, or vitamins.
To achieve the above objective, the present invention provides a method for improving skin such as whitening, improving elasticity, reducing wrinkles, moisturizing, or soothing the skin, which includes steps by applying a placenta-mimic composition to the skin.
To achieve the above objective, the present invention provides a method for improving skin such as whitening, improving elasticity, reducing wrinkles, moisturizing, or soothing the skin, which includes steps by administering a placenta-mimic composition to a subject.
To achieve the above objective, the present invention provides a use of a placenta-mimic composition including, as an active ingredient, Polydeoxyribonucleotide (PDRN) and Hydroxyethylpiperazine Ethane Sulfonic Acid (HEPES) which are recombined by by adding peptides, amino acids, or vitamins, for manufacturing the placenta-mimic composition that shows excellent skin improvement effects such as whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing.
Hereinafter, the placenta-mimic composition according to the present invention will be described in more detail.
In the present invention, growth factors, hormones, and cytokines with legal, ethical, and safety issues are excluded.
In the related art, a cosmetic composition including a placenta extract powder hydrolyzed with a proteolytic enzyme as an active ingredient (Korean Patent Laid-Open Publication No. 10-2009-0002444) and a cosmetic composition including growth factors and cytokines extracted from the placenta as active ingredients (Korean Registered Patent No. 10-1289062) are disclosed.
However, the above related arts are aimed at extracting components which have not had their safety confirmed and are legally regulated, such as growth-promoting factors, cytokines, epithelial cell-promoting factors, and the like from the placenta or optimizing a mixing ratio for reconstituting the composition to maximize the efficacy of the components. In addition, there is a difference in purpose because there is no description of safety verification for cosmetic compositions containing the aforementioned ingredients. Furthermore, in terms of measuring skin improvement effects, the prior arts suggest only subjective results of wrinkle improvement by visual inspection, rather than through quantitative analysis using specialized equipment to assess the efficacy of active ingredients for skin improvement, such as skin whitening, elasticity, moisturizing, or soothing anti-inflammatory effects. Therefore, Objective results based on above standardized testing methods for are not presented in prior arts, making it difficult to assess the extent of improvement.
On the other hand, specific embodiments of present invention suggest preparation of a placenta-mimic composition, in vitro and in vivo efficacy tests by using standard test methods or specialized analysis equipment. Through the embodiments of present invention, it was confirmed that the placenta-mimic composition, as an active ingredient, could significantly improve each skin conditions and maximize the efficacy of whitening, elasticity, wrinkle, moisturizing, or skin soothing.
In a specific embodiment of the present invention, further improved effects may be achieved by recombining PDRN and HEPES by adding peptides, amino acids, and vitamins.
Specifically, in an in vitro efficacy test, it was confirmed that the skin improvement effect of inhibiting melanin production, promoting collagen biosynthesis, promoting hyaluronic acid 1() biosynthesis, or inhibiting NO production was improved in Example 2 (including PDRN, HEPES, peptides, amino acids, and vitamins) compared to Example 1 (including PDRN, and HEPES). In addition, in an in vivo efficacy test, it was confirmed that the skin wrinkle improvement, elasticity improvement, whitening, or moisturizing effect was improved in Examples 3 and 4 (cosmetic composition including Example 2) compared to Comparative Examples 6 and 7 (cosmetic composition without Example 2). Furthermore, the cosmetic composition according to the present invention may eliminate the risk of unexpected contamination, impossibility of implementation (legal regulations), and consumer reluctance by recombining PDRN and HEPES
with additional peptides, amino acids, and vitamins.
In the present invention, as the peptides, one or more combinations selected from the group consisting of yeast polypeptides, oligopeptide-1, oligopeptide-2, copper tripeptide-1, and acetyl hexapeptide-8 may be used.
In the present invention, as the amino acids, one or more selected from the group consisting of arginine, tryptophan, threonine, lysine, valine, leucine, phenylalanine, histidine, isoleucine, tyrosine, potassium aspartate, sodium glutamate, glutamine, asparagine, proline, a lanine, glycine, and serine may be used.
In the present invention, as the vitamins, one or more selected from the group consisting of biotin, folic acid, cyanocobalamin, niacinamide, pantothenic acid, pyridoxine, riboflavin, and thiamine may be used.
One aspect of the present invention provides a cosmetic composition including the placenta-mimic composition as an active ingredient.
In the present invention, when the placenta-mimic composition is applied to a cosmetic composition, whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing efficacy can be exhibited, and specifically, a skin improvement effect may be obtained by inhibiting melanin synthesis, promoting collagen synthesis, promoting hyaluronic acid synthesis, or inhibiting NO production.
In the present invention, the cosmetic composition may be in a form of a general emulsified formulation and solubilized formulation. For example, the cosmetic composition may have a formulation such as a lotion such as softening lotion, nourishing lotion, or the like, an emulsion such as facial lotion, body lotion, or the like, a cream such as nourishing cream, moisture cream, eye cream, or the like, an essence, cosmetic ointment, balm, spray, gel, pack, sunscreen, makeup base, a foundation such as liquid type, solid type, spray type, or the like, powder, a makeup remover such as cleansing cream, cleansing lotion, cleansing oil, or the like, a cleanser such as cleansing foam, soap, body wash, or the like.
In addition, the cosmetic may include, in addition to the composition of the present invention, an adjuvant commonly used in the field of cosmetology, such as a fatty substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic emulsifier, a filler, metal ion sequestering and chelating agents, a preservative, a vitamin, a blocking agent, a wetting agent, an essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent, a lipid vesicle or, any other components commonly used in cosmetics.
The cosmetic formulation may include a relatively high concentration of the composition of the present invention in a case of wash-off type cosmetics such as makeup removers, cleansers, and the like in which active ingredients stay on the skin for a short period of time. On the other hand, in a case of leave-on type cosmetics such as lotions, emulsions, creams, essence, and the like in which active ingredients stay on the skin for a long period of time, it is acceptable to include the composition of the present invention at a low concentration relative to that used in the wash-off type cosmetics. Although not limited thereto, in a specific embodiment of the present invention, the composition of the present invention may include 0.001 to 5 parts by weight of the placenta-mimic composition based on a total weight of the composition, for example, 0.001 to 0.01 parts by weight, 0.001 to 0.1 parts by weight, 0.001 to 1 part by weight, 0.001 to
2.5 parts by weight, 0.01 to 0.1 parts by weight, 0.01 to 1 part by weight, 0.01 to 2.5 parts by weight, 0.01 to 5 parts by weight, 0.1 to 1 part by weight, 0.1 to 2.5 parts by weight, 0.1 to 5 parts by weight, 1 to 2.5 parts by weight, or 1 to 5 parts by weight.
When the placenta-mimic composition according to the present invention is included at less than 0.001 parts by weight of the total composition, a sufficient skin improvement effect may not be expected, and when it is included at more than 5 parts by weight thereof, unwanted reactions such as allergies may occur or problems with skin safety may occur, and thus, the above range is for preventing these outcomes.
Each of the above-mentioned components included in the cosmetic composition according to the present invention may be included in the cosmetic composition of the present invention, preferably, within a range that does not exceed a maximum usage amount specified in the regulations related to "Cosmetic Use Permission" stipulated by the government of each country.
For example, it may comply with the scope specified in the "Cosmetic Safety Technical Specifications" stipulated by the Chinese government.
Another aspect of the present invention provides a quasi-drug composition including the placenta-mimic composition as an active ingredient.
When the placenta-mimic composition of the present invention is applied to a quasi-drug composition, whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing efficacy can be exhibited, and specifically, a skin improvement effect may be obtained by inhibiting melanin synthesis, promoting collagen synthesis, promoting hyaluronic acid synthesis, or inhibition of NO production.
The quasi-drug composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent, if necessary. The pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it can achieve the effects of the present invention, and may include, for example, a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, a lubricant, a sweetener, a flavoring agent, a preservative, and the like.
The carrier, excipient, or diluent of the present invention is commonly used, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, without being limited thereto.
The quasi-drug composition may be used in any form suitable for pharmaceutical preparations, including oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and the like, external preparations such as ointments, creams, and the like, suppositories, sterile injection solutions, and the like, and may further include dispersants or stabilizers. Although not limited thereto, in a specific embodiment of the present invention, the composition of the present invention may include 0.001 to 5 parts by weight of the placenta-mimic composition based on a total weight of the composition, for example, 0.001 to 0.01 parts by weight, 0.001 to 0.1 parts by weight, 0.001 to 1 part by weight, 0.001 to 2.5 parts by weight, 0.01 to 0.1 parts by weight, 0.01 to 1 part by weight, 0.01 to 2.5 parts by weight, 0.01 to 5 parts by weight, 0.1 to 1 part by weight, 0.1 to 2.5 parts by weight, 0.1 to 5 parts by weight, 1 to 2.5 parts by weight, or 1 to 5 parts by weight.
When the placenta-mimic composition according to the present invention is included at less than 0.001 parts by weight of the total composition, a sufficient skin improvement effect may not be expected, and when it is included at more than 5 parts by weight thereof, unwanted reactions such as allergies may occur or problems with skin safety may occur, and thus, the above range is for preventing these outcomes.
[Advantageous Effects]
A placenta-mimic cosmetic composition according to the present invention can show excellent skin improvement effects such as whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing by adding hydroxyethylpiperazine ethane sulfonic acid (HEPES) to polydeoxyribonucleotide (PDRN), which is an active ingredient in the placenta, and adding peptides, amino acids, or vitamins to recombine.
[Best Mode]
Hereinafter, the present invention will be explained in detail with the following examples.
However, the following examples only illustrate the present invention, and the content of the present invention is not limited to the following examples.
Specific examples of a placenta-mimic composition according to the present invention are illustrated below.
Preparation Example 1. Preparation of Examples and Comparative Examples of Placenta-mimic Composition In order to evaluate whitening, collagen biosynthesis, moisturizing, and soothing effects of the placenta-mimic composition of the present invention, Examples and Comparative Examples were prepared as shown in Table 1 below.
[Table 11 Comp Comp Comp Exam Comp Comp Exam arative arative arative pie 1 arative arative pie 2 Exam Exam Exam Exam Exam pie 1 pie 2 pie 3 pie 4 pie 5 PDRN 0.2 0.2 0.2 0.2 HEPES 0.4 0.4 0.4 0.4 -0 Oligopeptide-1 - 0.01 -0.01 0.01 0.01 m r,- a Oligopeptide-2 - 0.01 -0.01 0.01 0.01 m v) Copper tripeptide-1 - 0.01 - 0.01 0.01 0.01 Acetyl hexapeptide-8 - 0.01 - 0.01 0.01 0.01 Yeast polypeptide 0.1 0.1 0.1 0.1 > Arginine 0.3 0.3 0.3 0.3 B
g Tryptophan 0.1 0.1 0.1 0.1 >
m Threonine -0.05 - 0.05 0.05 0.05 Ei v) Lysine - 0.04 - 0.04 0.04 0.04 Valine - 0.02 - 0.02 0.02 0.02 Leucine - 0.02 - 0.02 0.02 0.02 Phenylalanine - 0.02 - 0.02 0.02 0.02 H istidine - 0.01 - 0.01 0.01 0.01 Isoleucine - 0.01 - 0.01 0.01 0.01 Tyrosine - 0.02 - 0.02 0.02 0.02 Potassium aspartate - 0.18 - 0.18 0.18 0.18 Sodium glutamate - 0.34 - 0.34 0.34 0.34 Glutamine 0.1 0.1 0.1 0.1 Aspa rag i ne 0.1 0.1 0.1 0.1 Proline 0.1 0.1 0.1 0.1 Alanine - 0.08 - 0.08 0.08 0.08 Glycine - 0.06 - 0.06 0.06 0.06 Serine - 0.04 - 0.04 0.04 0.04 < Biotin 0.1 0.1 0.1 0.1 c) Fol ic Acid 0.1 0.1 0.1 0.1 s=
v, Cyanocoba la mi n 0.1 0.1 0.1 0.1 Niacinamide - - 0.1 - 0.1 0.1 0.1 Pantothenic acid - - 0.1 - 0.1 0.1 0.1 Pyridoxine - - 0.1 - 0.1 0.1 0.1 Riboflavin - - 0.1 - 0.1 0.1 0.1 Thiamine - - 0.1 - 0.1 0.1 0.1 Butylene glycol 20 20 20 20 20 20 Purified water up to up to up to up to up to up to up to Experimental Example 1: Whitening evaluation (Melanin content evaluation) M NT-1 melanoma cells were seeded in a 6-well plate at a concentration of 1-2 x 105 cells/ml and cultured for 24 hours. Samples including each of Comparative Examples and Examples at concentrations shown in Table 2 below were prepared in DMEM
medium, the cultured melanoma cells were treated with the samples, and further cultured for 72 hours. At this time, a DM EM medium to which no other components were added was used as a control group.
When the culture was completed, the cells were collected, centrifuged at 13,000 rpm for 1 minute, and the supernatant was removed, and thereafter, lysis was performed by adding 300 I of 0.5%
Triton X-100 solution to a pellet. This was centrifuged again at 13,000 rpm for 3 minutes, and the pellet and supernatant were separately collected. 100 I of 0.5N NaOH was added to the cell pellet, incubated overnight to dissolve melanin, and thereafter, an absorbance at 450 nm was measured using an ELISA reader. The ability to inhibit melanin synthesis was evaluated as follows.
Melanin content in control group ¨ melanin content in sample Ability to inhibit melanin synthesis (%) = ( ) x 100 Melanin content in control group The results are shown in Table 2 below.
[Table 2]
Treatment Ability to inhibit melanin synthesis (relative value concentration compared to control group, %) Comparative 0.01% _ Example 1 Comparative 0.01% _ Example 2 Comparative 0.01%
0.2 Example 3 Example 1 0.01% 6.8 Comparative 0.01%
8.4 Example 4 Comparative 0.01%
0.2 Example 5 Example 2 0.01% 25.2 -: No effect As shown in Table 2, Examples 1 and 2 showed an effect of inhibiting melanin synthesis.
Comparative Example 1 including only PDRN had no effect at all, whereas it was confirmed that the ability to inhibit melanin synthesis was increased when recombination with HEPES (Example 1) or peptides, amino acids, and vitamins (Comparative Example 4) was made. In particular, Example 2 showed the best ability to inhibit melanin synthesis, indicating that there is a synergistic efficacy in inhibiting melanin synthesis when PDRN is recombined by adding HEPES, peptides, amino acids, and vitamins.
1(:) Experimental Example 2: Elasticity improvement evaluation (Collagen biosynthesis evaluation) Skin fibroblasts were seeded in a 48-well plate at a concentration of 2-5 x 104 cells/ml and cultured for 24 hours. After removing a growth medium, samples including each of the Comparative Examples and Examples at concentrations shown in Table 3 below were prepared in DM EM medium, the cultured skin fibroblasts were treated with the samples, and further cultured for 24 hours. At this time, a DMEM medium to which no other components were added was used as a control group. When culture was completed, the cell culture medium was taken and [LISA assay was performed. The human procollagen 1a1 duoset ELISA kit used in this experiment was a product of R&D Systems, and evaluation was performed according to the experimental protocol provided by the manufacturer. Collagen biosynthesis was evaluated as follows.
1 ( Sample value ) Collagen biosynthesis (%) = _________________________________ x 1001¨ 100 Control group value' The results are shown in Table 3 below.
[Table 3]
Treatment Collagen Biosynthesis (relative value compared to Concentration control group, %) Comparative 0.01%
When the placenta-mimic composition according to the present invention is included at less than 0.001 parts by weight of the total composition, a sufficient skin improvement effect may not be expected, and when it is included at more than 5 parts by weight thereof, unwanted reactions such as allergies may occur or problems with skin safety may occur, and thus, the above range is for preventing these outcomes.
Each of the above-mentioned components included in the cosmetic composition according to the present invention may be included in the cosmetic composition of the present invention, preferably, within a range that does not exceed a maximum usage amount specified in the regulations related to "Cosmetic Use Permission" stipulated by the government of each country.
For example, it may comply with the scope specified in the "Cosmetic Safety Technical Specifications" stipulated by the Chinese government.
Another aspect of the present invention provides a quasi-drug composition including the placenta-mimic composition as an active ingredient.
When the placenta-mimic composition of the present invention is applied to a quasi-drug composition, whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing efficacy can be exhibited, and specifically, a skin improvement effect may be obtained by inhibiting melanin synthesis, promoting collagen synthesis, promoting hyaluronic acid synthesis, or inhibition of NO production.
The quasi-drug composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent, if necessary. The pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it can achieve the effects of the present invention, and may include, for example, a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, a lubricant, a sweetener, a flavoring agent, a preservative, and the like.
The carrier, excipient, or diluent of the present invention is commonly used, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, without being limited thereto.
The quasi-drug composition may be used in any form suitable for pharmaceutical preparations, including oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and the like, external preparations such as ointments, creams, and the like, suppositories, sterile injection solutions, and the like, and may further include dispersants or stabilizers. Although not limited thereto, in a specific embodiment of the present invention, the composition of the present invention may include 0.001 to 5 parts by weight of the placenta-mimic composition based on a total weight of the composition, for example, 0.001 to 0.01 parts by weight, 0.001 to 0.1 parts by weight, 0.001 to 1 part by weight, 0.001 to 2.5 parts by weight, 0.01 to 0.1 parts by weight, 0.01 to 1 part by weight, 0.01 to 2.5 parts by weight, 0.01 to 5 parts by weight, 0.1 to 1 part by weight, 0.1 to 2.5 parts by weight, 0.1 to 5 parts by weight, 1 to 2.5 parts by weight, or 1 to 5 parts by weight.
When the placenta-mimic composition according to the present invention is included at less than 0.001 parts by weight of the total composition, a sufficient skin improvement effect may not be expected, and when it is included at more than 5 parts by weight thereof, unwanted reactions such as allergies may occur or problems with skin safety may occur, and thus, the above range is for preventing these outcomes.
[Advantageous Effects]
A placenta-mimic cosmetic composition according to the present invention can show excellent skin improvement effects such as whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing by adding hydroxyethylpiperazine ethane sulfonic acid (HEPES) to polydeoxyribonucleotide (PDRN), which is an active ingredient in the placenta, and adding peptides, amino acids, or vitamins to recombine.
[Best Mode]
Hereinafter, the present invention will be explained in detail with the following examples.
However, the following examples only illustrate the present invention, and the content of the present invention is not limited to the following examples.
Specific examples of a placenta-mimic composition according to the present invention are illustrated below.
Preparation Example 1. Preparation of Examples and Comparative Examples of Placenta-mimic Composition In order to evaluate whitening, collagen biosynthesis, moisturizing, and soothing effects of the placenta-mimic composition of the present invention, Examples and Comparative Examples were prepared as shown in Table 1 below.
[Table 11 Comp Comp Comp Exam Comp Comp Exam arative arative arative pie 1 arative arative pie 2 Exam Exam Exam Exam Exam pie 1 pie 2 pie 3 pie 4 pie 5 PDRN 0.2 0.2 0.2 0.2 HEPES 0.4 0.4 0.4 0.4 -0 Oligopeptide-1 - 0.01 -0.01 0.01 0.01 m r,- a Oligopeptide-2 - 0.01 -0.01 0.01 0.01 m v) Copper tripeptide-1 - 0.01 - 0.01 0.01 0.01 Acetyl hexapeptide-8 - 0.01 - 0.01 0.01 0.01 Yeast polypeptide 0.1 0.1 0.1 0.1 > Arginine 0.3 0.3 0.3 0.3 B
g Tryptophan 0.1 0.1 0.1 0.1 >
m Threonine -0.05 - 0.05 0.05 0.05 Ei v) Lysine - 0.04 - 0.04 0.04 0.04 Valine - 0.02 - 0.02 0.02 0.02 Leucine - 0.02 - 0.02 0.02 0.02 Phenylalanine - 0.02 - 0.02 0.02 0.02 H istidine - 0.01 - 0.01 0.01 0.01 Isoleucine - 0.01 - 0.01 0.01 0.01 Tyrosine - 0.02 - 0.02 0.02 0.02 Potassium aspartate - 0.18 - 0.18 0.18 0.18 Sodium glutamate - 0.34 - 0.34 0.34 0.34 Glutamine 0.1 0.1 0.1 0.1 Aspa rag i ne 0.1 0.1 0.1 0.1 Proline 0.1 0.1 0.1 0.1 Alanine - 0.08 - 0.08 0.08 0.08 Glycine - 0.06 - 0.06 0.06 0.06 Serine - 0.04 - 0.04 0.04 0.04 < Biotin 0.1 0.1 0.1 0.1 c) Fol ic Acid 0.1 0.1 0.1 0.1 s=
v, Cyanocoba la mi n 0.1 0.1 0.1 0.1 Niacinamide - - 0.1 - 0.1 0.1 0.1 Pantothenic acid - - 0.1 - 0.1 0.1 0.1 Pyridoxine - - 0.1 - 0.1 0.1 0.1 Riboflavin - - 0.1 - 0.1 0.1 0.1 Thiamine - - 0.1 - 0.1 0.1 0.1 Butylene glycol 20 20 20 20 20 20 Purified water up to up to up to up to up to up to up to Experimental Example 1: Whitening evaluation (Melanin content evaluation) M NT-1 melanoma cells were seeded in a 6-well plate at a concentration of 1-2 x 105 cells/ml and cultured for 24 hours. Samples including each of Comparative Examples and Examples at concentrations shown in Table 2 below were prepared in DMEM
medium, the cultured melanoma cells were treated with the samples, and further cultured for 72 hours. At this time, a DM EM medium to which no other components were added was used as a control group.
When the culture was completed, the cells were collected, centrifuged at 13,000 rpm for 1 minute, and the supernatant was removed, and thereafter, lysis was performed by adding 300 I of 0.5%
Triton X-100 solution to a pellet. This was centrifuged again at 13,000 rpm for 3 minutes, and the pellet and supernatant were separately collected. 100 I of 0.5N NaOH was added to the cell pellet, incubated overnight to dissolve melanin, and thereafter, an absorbance at 450 nm was measured using an ELISA reader. The ability to inhibit melanin synthesis was evaluated as follows.
Melanin content in control group ¨ melanin content in sample Ability to inhibit melanin synthesis (%) = ( ) x 100 Melanin content in control group The results are shown in Table 2 below.
[Table 2]
Treatment Ability to inhibit melanin synthesis (relative value concentration compared to control group, %) Comparative 0.01% _ Example 1 Comparative 0.01% _ Example 2 Comparative 0.01%
0.2 Example 3 Example 1 0.01% 6.8 Comparative 0.01%
8.4 Example 4 Comparative 0.01%
0.2 Example 5 Example 2 0.01% 25.2 -: No effect As shown in Table 2, Examples 1 and 2 showed an effect of inhibiting melanin synthesis.
Comparative Example 1 including only PDRN had no effect at all, whereas it was confirmed that the ability to inhibit melanin synthesis was increased when recombination with HEPES (Example 1) or peptides, amino acids, and vitamins (Comparative Example 4) was made. In particular, Example 2 showed the best ability to inhibit melanin synthesis, indicating that there is a synergistic efficacy in inhibiting melanin synthesis when PDRN is recombined by adding HEPES, peptides, amino acids, and vitamins.
1(:) Experimental Example 2: Elasticity improvement evaluation (Collagen biosynthesis evaluation) Skin fibroblasts were seeded in a 48-well plate at a concentration of 2-5 x 104 cells/ml and cultured for 24 hours. After removing a growth medium, samples including each of the Comparative Examples and Examples at concentrations shown in Table 3 below were prepared in DM EM medium, the cultured skin fibroblasts were treated with the samples, and further cultured for 24 hours. At this time, a DMEM medium to which no other components were added was used as a control group. When culture was completed, the cell culture medium was taken and [LISA assay was performed. The human procollagen 1a1 duoset ELISA kit used in this experiment was a product of R&D Systems, and evaluation was performed according to the experimental protocol provided by the manufacturer. Collagen biosynthesis was evaluated as follows.
1 ( Sample value ) Collagen biosynthesis (%) = _________________________________ x 1001¨ 100 Control group value' The results are shown in Table 3 below.
[Table 3]
Treatment Collagen Biosynthesis (relative value compared to Concentration control group, %) Comparative 0.01%
3.4 Example 1 Comparative 0.01% _ Example 2 Comparative 0.01%
5.2 Example 3 Example 1 0.01% 6.8 Comparative 0.01%
5.7 Example 4 Comparative 0.01%
3.6 Example 5 Example 2 0.01% 46.7 -: No effect As shown in Table 3, Examples 1 and 2 showed an effect of promoting collagen biosynthesis. Compared to the effect of Comparative Example 1 including only PDRN, it was confirmed that the effect of promoting collagen biosynthesis was increased when recombination with HEPES (Example 1) or peptides, amino acids, and vitamins (Comparative Example 4) was made. In particular, Example 2 showed the best effect in promoting collagen biosynthesis, indicating that there is a synergistic efficacy in promoting collagen biosynthesis when PDRN is recombined by adding HEPES, peptides, amino acids, and vitamins.
Experimental Example 3: Moisturizing evaluation (Hyaluronic acid biosynthesis evaluation) HaCaT, a human keratinocyte, was seeded in a 48-well plate at a concentration of 2-5 x 104 cells/ml and cultured for 24 hours. After removing a growth medium, samples including each of the Comparative Examples and Examples at the concentrations shown in Table
5.2 Example 3 Example 1 0.01% 6.8 Comparative 0.01%
5.7 Example 4 Comparative 0.01%
3.6 Example 5 Example 2 0.01% 46.7 -: No effect As shown in Table 3, Examples 1 and 2 showed an effect of promoting collagen biosynthesis. Compared to the effect of Comparative Example 1 including only PDRN, it was confirmed that the effect of promoting collagen biosynthesis was increased when recombination with HEPES (Example 1) or peptides, amino acids, and vitamins (Comparative Example 4) was made. In particular, Example 2 showed the best effect in promoting collagen biosynthesis, indicating that there is a synergistic efficacy in promoting collagen biosynthesis when PDRN is recombined by adding HEPES, peptides, amino acids, and vitamins.
Experimental Example 3: Moisturizing evaluation (Hyaluronic acid biosynthesis evaluation) HaCaT, a human keratinocyte, was seeded in a 48-well plate at a concentration of 2-5 x 104 cells/ml and cultured for 24 hours. After removing a growth medium, samples including each of the Comparative Examples and Examples at the concentrations shown in Table
4 below were prepared in DM EM medium, the cultured HaCaT were treated with the samples, and further cultured for 48 hours. At this time, a DM EM medium to which no other components were added was used as a control group. When the culture was completed, the cell culture medium was taken, and the moisturizing ability was evaluated by comparing hyaluronic acid synthesis with the control group using Quantikine ELISA Hyaluronan from R&D Systems. Hyaluronic acid biosynthesis was evaluated as follows.
1 ( Sample value ) Hyaluronic acid biosynthesis (%) = x 1001¨ 100 Control group value' The results are shown in Table 4 below.
[Table 41 Treatment Hyaluronic Acid Biosynthesis (relative value compared Concentration to control group, %) Comparative 0.01% _ Example 1 Comparative 0.01% _ Example 2 Comparative 0.01% 3.3 Example 3 Example 1 0.01% 8.2 Comparative 0.01%
1.2 Example 4 Comparative 0.01%
0.5 Example 5 Example 2 0.01% 25.5 -: No effect As shown in Table 4, Examples 1 and 2 showed an effect of promoting hyaluronic acid biosynthesis. Comparative Example 1 including only PDRN had no effect at all, whereas it was confirmed that the promotion of hyaluronic acid biosynthesis was increased when recombination with HEPES (Example 1) or peptides, amino acids, and vitamins (Comparative Example 4) was made. In particular, Example 2 showed the best effect in promoting hyaluronic acid biosynthesis, indicating that there is a synergistic efficacy in promoting hyaluronic acid biosynthesis when PDRN is recombined by adding HEPES, peptides, amino acids, and vitamins.
Experimental Example 4: Skin soothing evaluation (NO production inhibition evaluation) Raw 264.7 cells, macrophages, were seeded in a 24-well plate at a concentration of 2 x 104 cells/ml and cultured for 24 hours. After removing a growth medium, samples including each of the Comparative Examples and Examples at concentrations shown in Table 5 below were prepared in RPM! medium and the cultured macrophages were treated with the samples for 30 minutes. At this time, an RPM I medium to which no other components were added was used as a control group. After sample treatment, 1 ug/ml of LPS was further treated and further cultured for another 24 hours. Subsequently, the ability to inhibit NO production was evaluated using an NO quantification kit as follows.
( Sample value )1 Ability to inhibit NO production (%) = 11 x 100 Control group value The results are shown in Table 5 below.
[Table 5]
Treatment Inhibition of NO Production (Relative value compared to Concentration control group, %) Comparative 0.1%
16.2 Example 1 Comparative 0.1%
15.4 Example 2 Comparative 0.1%
1.1 Example 3 Example 1 0.1% 15.5 Comparative 0.1%
15.9 Example 4 Comparative 0.1%
15.2 Example 5 Example 2 0.1% 43.0 As shown in Table 5, Examples 1 and 2 showed an effect of inhibiting NO
production.
Compared to the effect of Comparative Example 1 including only PDRN, it was confirmed that the effect of inhibiting NO production was significantly increased when recombination with HEPES, peptides, amino acids, and vitamins (Example 2) was made. This shows that there is a synergistic efficacy in inhibiting NO production when PDRN is recombined by adding HEPES, 1() peptides, amino acids, and vitamins.
Preparation Example 2. Preparation of Example and Comparative Example of Cosmetic Compositions Including Placenta-mimic Composition for Skin Wrinkle, Elasticity, Whitening and Moisturizing Human Tests In order to evaluate the effect of the placenta-mimic composition on human skin, an Example and a Comparative Example were prepared as cream formulations with the compositions shown in Table 6 below and tested (units: weight%).
[Table 6]
Comparative Example Example 6 Example 2 0 1 Purified water up to 100 up to 100 Glycerin 8.0 8.0 Butylene glycol 4.0 4.0 Hyaluronic acid extract 5.0 5.0 Beta-glucan 7.0 7.0 Carbomer 0.15 0.15 Caprylic/Capric triglyceride 8.0 8.0 Squalane 5.0 5.0 Cetearyl glucoside 1.5 1.5 Sorbitan stearate 0.4 0.4 Cetearyl alcohol 2.0 2.0 Preservative Appropriate Appropriate amount amount Pigment Appropriate Appropriate amount amount Triethanolamine 0.15 0.15 Experimental Example 5. Skin wrinkles, elasticity, whitening, and moisturizing human test evaluation After Example 3 and Comparative Example 6 were applied to the right and left sides of the face of 20 women aged 30 to 50 twice a day in the morning and evening for 8 weeks, respectively, skin wrinkles, elasticity, whitening, and moisturizing effects were measured by the 1() following methods. An improvement rate of each effect was evaluated as follows.
Measured value after use ¨ measured value before use) Improvement rate (%) = I
______________________________________________________________ I x 100 Measured value before use First, skin wrinkles were measured once around the eyes using Antera 3D CS
(Miravex, Ireland) equipment, and a depth (mm) of a Wrinkle-small analysis mode was used as evaluation data. The measuring device is a device that can measure a surface image of the skin using a light emitting diode (LED light source), extracts data from a 3D shape image of a built-in program, digitizes the skin condition, and utilizes the image. The results are shown in Table 7 below.
[Table 7]
Wrinkle depth improvement rate around the eyes (%) Comparative Example 6 2.1 Example 3 10.8 As shown in the results in Table 7, a group treated with Example 3 was found to have an excellent wrinkle improvement effect by improving skin wrinkles by 510% or more compared to Comparative Example 6.
Next, the skin elasticity improvement effect was measured using a skin elasticity measuring device (Cutometer SEM 575, C+K Electronic Co., Germany), and the result refers to the skin viscoelasticity measured by the skin elasticity measuring device. The results are shown in Table 8 below.
[Table 8]
Skin elasticity improvement rate (%) Comparative Example 6 4.2 Example 3 12.9 As shown in the results in Table 8, the group treated with Example 3 was found to have an excellent skin elasticity effect by improving skin elasticity by 300% or more compared to Comparative Example 6.
Subsequently, a degree of skin tone improvement was evaluated for skin whitening using a Facial Stage DM-3 (Moritex, Japan) device. A skin tone improvement rate was determined by skin brightness and color change values based on skin lightness and color measurement values.
The results are shown in Table 9 below.
[Table 91 Comparative Example 6 Example Skin tone improvement rate (%) Brightness (mean standard Brightness (mean standard deviation) deviation) 0.5 0.1 2.0 0.3 Color (mean standard deviation) Color (mean standard deviation) 0.7 0.4 1.8 0.2 As shown in the results in Table 9, the group treated with Example 3 was found to have an excellent skin whitening effect by improving brightness by 400% or more and color by 250%
or more compared to Comparative Example 6.
Next, for skin moisturizing, specifically, after washing the face with soap, the skin was adapted to constant temperature and humidity conditions (temperature 20 2 C, relative humidity 40 2%). Using a corneometer (CM825), skin surface capacitance was measured three times repeatedly. The results are shown in Table 10 below.
[Table 10]
Moisture improvement rate (%) Comparative Example 6 7.2 Example 3 22.9 As shown in the results in Table 10, the group treated with Example 3 was found to have an excellent skin moisturizing effect by increasing moisture by 310% or more compared to Comparative Example 6.
Preparation Example 3. Preparation of Example and Comparative Example of Cosmetic Compositions Including Placenta-mimic Composition for Skin Soothing Human Test In order to evaluate the soothing effect of the placenta-mimic composition on human skin,
1 ( Sample value ) Hyaluronic acid biosynthesis (%) = x 1001¨ 100 Control group value' The results are shown in Table 4 below.
[Table 41 Treatment Hyaluronic Acid Biosynthesis (relative value compared Concentration to control group, %) Comparative 0.01% _ Example 1 Comparative 0.01% _ Example 2 Comparative 0.01% 3.3 Example 3 Example 1 0.01% 8.2 Comparative 0.01%
1.2 Example 4 Comparative 0.01%
0.5 Example 5 Example 2 0.01% 25.5 -: No effect As shown in Table 4, Examples 1 and 2 showed an effect of promoting hyaluronic acid biosynthesis. Comparative Example 1 including only PDRN had no effect at all, whereas it was confirmed that the promotion of hyaluronic acid biosynthesis was increased when recombination with HEPES (Example 1) or peptides, amino acids, and vitamins (Comparative Example 4) was made. In particular, Example 2 showed the best effect in promoting hyaluronic acid biosynthesis, indicating that there is a synergistic efficacy in promoting hyaluronic acid biosynthesis when PDRN is recombined by adding HEPES, peptides, amino acids, and vitamins.
Experimental Example 4: Skin soothing evaluation (NO production inhibition evaluation) Raw 264.7 cells, macrophages, were seeded in a 24-well plate at a concentration of 2 x 104 cells/ml and cultured for 24 hours. After removing a growth medium, samples including each of the Comparative Examples and Examples at concentrations shown in Table 5 below were prepared in RPM! medium and the cultured macrophages were treated with the samples for 30 minutes. At this time, an RPM I medium to which no other components were added was used as a control group. After sample treatment, 1 ug/ml of LPS was further treated and further cultured for another 24 hours. Subsequently, the ability to inhibit NO production was evaluated using an NO quantification kit as follows.
( Sample value )1 Ability to inhibit NO production (%) = 11 x 100 Control group value The results are shown in Table 5 below.
[Table 5]
Treatment Inhibition of NO Production (Relative value compared to Concentration control group, %) Comparative 0.1%
16.2 Example 1 Comparative 0.1%
15.4 Example 2 Comparative 0.1%
1.1 Example 3 Example 1 0.1% 15.5 Comparative 0.1%
15.9 Example 4 Comparative 0.1%
15.2 Example 5 Example 2 0.1% 43.0 As shown in Table 5, Examples 1 and 2 showed an effect of inhibiting NO
production.
Compared to the effect of Comparative Example 1 including only PDRN, it was confirmed that the effect of inhibiting NO production was significantly increased when recombination with HEPES, peptides, amino acids, and vitamins (Example 2) was made. This shows that there is a synergistic efficacy in inhibiting NO production when PDRN is recombined by adding HEPES, 1() peptides, amino acids, and vitamins.
Preparation Example 2. Preparation of Example and Comparative Example of Cosmetic Compositions Including Placenta-mimic Composition for Skin Wrinkle, Elasticity, Whitening and Moisturizing Human Tests In order to evaluate the effect of the placenta-mimic composition on human skin, an Example and a Comparative Example were prepared as cream formulations with the compositions shown in Table 6 below and tested (units: weight%).
[Table 6]
Comparative Example Example 6 Example 2 0 1 Purified water up to 100 up to 100 Glycerin 8.0 8.0 Butylene glycol 4.0 4.0 Hyaluronic acid extract 5.0 5.0 Beta-glucan 7.0 7.0 Carbomer 0.15 0.15 Caprylic/Capric triglyceride 8.0 8.0 Squalane 5.0 5.0 Cetearyl glucoside 1.5 1.5 Sorbitan stearate 0.4 0.4 Cetearyl alcohol 2.0 2.0 Preservative Appropriate Appropriate amount amount Pigment Appropriate Appropriate amount amount Triethanolamine 0.15 0.15 Experimental Example 5. Skin wrinkles, elasticity, whitening, and moisturizing human test evaluation After Example 3 and Comparative Example 6 were applied to the right and left sides of the face of 20 women aged 30 to 50 twice a day in the morning and evening for 8 weeks, respectively, skin wrinkles, elasticity, whitening, and moisturizing effects were measured by the 1() following methods. An improvement rate of each effect was evaluated as follows.
Measured value after use ¨ measured value before use) Improvement rate (%) = I
______________________________________________________________ I x 100 Measured value before use First, skin wrinkles were measured once around the eyes using Antera 3D CS
(Miravex, Ireland) equipment, and a depth (mm) of a Wrinkle-small analysis mode was used as evaluation data. The measuring device is a device that can measure a surface image of the skin using a light emitting diode (LED light source), extracts data from a 3D shape image of a built-in program, digitizes the skin condition, and utilizes the image. The results are shown in Table 7 below.
[Table 7]
Wrinkle depth improvement rate around the eyes (%) Comparative Example 6 2.1 Example 3 10.8 As shown in the results in Table 7, a group treated with Example 3 was found to have an excellent wrinkle improvement effect by improving skin wrinkles by 510% or more compared to Comparative Example 6.
Next, the skin elasticity improvement effect was measured using a skin elasticity measuring device (Cutometer SEM 575, C+K Electronic Co., Germany), and the result refers to the skin viscoelasticity measured by the skin elasticity measuring device. The results are shown in Table 8 below.
[Table 8]
Skin elasticity improvement rate (%) Comparative Example 6 4.2 Example 3 12.9 As shown in the results in Table 8, the group treated with Example 3 was found to have an excellent skin elasticity effect by improving skin elasticity by 300% or more compared to Comparative Example 6.
Subsequently, a degree of skin tone improvement was evaluated for skin whitening using a Facial Stage DM-3 (Moritex, Japan) device. A skin tone improvement rate was determined by skin brightness and color change values based on skin lightness and color measurement values.
The results are shown in Table 9 below.
[Table 91 Comparative Example 6 Example Skin tone improvement rate (%) Brightness (mean standard Brightness (mean standard deviation) deviation) 0.5 0.1 2.0 0.3 Color (mean standard deviation) Color (mean standard deviation) 0.7 0.4 1.8 0.2 As shown in the results in Table 9, the group treated with Example 3 was found to have an excellent skin whitening effect by improving brightness by 400% or more and color by 250%
or more compared to Comparative Example 6.
Next, for skin moisturizing, specifically, after washing the face with soap, the skin was adapted to constant temperature and humidity conditions (temperature 20 2 C, relative humidity 40 2%). Using a corneometer (CM825), skin surface capacitance was measured three times repeatedly. The results are shown in Table 10 below.
[Table 10]
Moisture improvement rate (%) Comparative Example 6 7.2 Example 3 22.9 As shown in the results in Table 10, the group treated with Example 3 was found to have an excellent skin moisturizing effect by increasing moisture by 310% or more compared to Comparative Example 6.
Preparation Example 3. Preparation of Example and Comparative Example of Cosmetic Compositions Including Placenta-mimic Composition for Skin Soothing Human Test In order to evaluate the soothing effect of the placenta-mimic composition on human skin,
5% of lactic acid, a skin irritant, was added, and an Example and a Comparative Example were prepared as cream formulations with the compositions shown in Table 11 below and tested (units:
weight%).
[Table 111 Comparative Example 4 Example 7 Example 2 0 Purified Water up to 100 up to 100 Lactic acid 5 Glycerin 8.0 8.0 Butylene glycol 4.0 4.0 Hyaluronic acid 5.0 5.0 Beta-glucan 7.0 7.0 Carbomer 0.15 0.15 Caprylic/Capric triglyceride 8.0 8.0 Squalane 5.0 5.0 Cetearyl glucoside 1.5 1.5 Sorbitan stearate 0.4 0.4 Cetearyl alcohol 2.0 2.0 Preservative Appropriate Appropriate amount amount Pigment Appropriate Appropriate amount amount Triethanolamine 0.15 0.15 Experimental Example 6. Skin soothing human test evaluation The skin soothing effect was confirmed through a human skin patch experiment on 20 healthy adult men and women in their 20s to 40s without skin disease or allergy symptoms and no history of hypersensitivity.
After sufficiently wiping the inside of the forearm of the subject with 70%
ethanol, it was completely dried, and 30 jig each of Example 4 and Comparative Example 7 according to Preparation Example 3 was applied to the right and left sides. After 24 hours had elapsed based on the patch application time, the patch was removed, and approximately 30 minutes later, the patch area was observed using a magnifying glass (M icroView) to confirm the presence or absence of erythema and edema. Evaluation was conducted based on criteria in Table 12 below.
[Table 121 Symbol Score Skin Evaluation Criteria Reaction - 0 No irritation No reaction + 0.5 Little Faint or minimal erythema irritation + 1 Mild Erythema with clear boundaries but mild erythema irritation ++ 2 Moderate Marked erythema irritation +++ 3 Strong Severe erythema and blisters irritation Based on scores in Table 12 above, an average skin reactivity was calculated according to the formula below. The skin reaction results were calculated according to the formula below as a value proportional to a degree of irritation based on 100% for 3 points with the strongest skin irritation. In this case, the number of reactions is the number of subjects corresponding to each score.
E (Score x number of reactions) Average skin reactivity = . ____________________________ .
x 100 [Maximum score x total number of subjects]
The results are shown in Table 13 below.
[Table 13]
Average skin reactivity Comparative Example 7 12.5 Example 4 3.3 As shown in the results in Table 13, a group treated with Example 4 was found to have an excellent skin soothing effect by improving skin reactivity by 370% or more compared to Comparative Example 7.
[Industrial Applicability]
A placenta-mimic cosmetic composition according to the present invention can show excellent skin improvement effects such as whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing by adding hydroxyethylpiperazine ethane sulfonic acid (HEPES) to polydeoxyribonucleotide (PDRN), which is an active ingredient in the placenta, and adding peptides, amino acids, or vitamins to recombine.
weight%).
[Table 111 Comparative Example 4 Example 7 Example 2 0 Purified Water up to 100 up to 100 Lactic acid 5 Glycerin 8.0 8.0 Butylene glycol 4.0 4.0 Hyaluronic acid 5.0 5.0 Beta-glucan 7.0 7.0 Carbomer 0.15 0.15 Caprylic/Capric triglyceride 8.0 8.0 Squalane 5.0 5.0 Cetearyl glucoside 1.5 1.5 Sorbitan stearate 0.4 0.4 Cetearyl alcohol 2.0 2.0 Preservative Appropriate Appropriate amount amount Pigment Appropriate Appropriate amount amount Triethanolamine 0.15 0.15 Experimental Example 6. Skin soothing human test evaluation The skin soothing effect was confirmed through a human skin patch experiment on 20 healthy adult men and women in their 20s to 40s without skin disease or allergy symptoms and no history of hypersensitivity.
After sufficiently wiping the inside of the forearm of the subject with 70%
ethanol, it was completely dried, and 30 jig each of Example 4 and Comparative Example 7 according to Preparation Example 3 was applied to the right and left sides. After 24 hours had elapsed based on the patch application time, the patch was removed, and approximately 30 minutes later, the patch area was observed using a magnifying glass (M icroView) to confirm the presence or absence of erythema and edema. Evaluation was conducted based on criteria in Table 12 below.
[Table 121 Symbol Score Skin Evaluation Criteria Reaction - 0 No irritation No reaction + 0.5 Little Faint or minimal erythema irritation + 1 Mild Erythema with clear boundaries but mild erythema irritation ++ 2 Moderate Marked erythema irritation +++ 3 Strong Severe erythema and blisters irritation Based on scores in Table 12 above, an average skin reactivity was calculated according to the formula below. The skin reaction results were calculated according to the formula below as a value proportional to a degree of irritation based on 100% for 3 points with the strongest skin irritation. In this case, the number of reactions is the number of subjects corresponding to each score.
E (Score x number of reactions) Average skin reactivity = . ____________________________ .
x 100 [Maximum score x total number of subjects]
The results are shown in Table 13 below.
[Table 13]
Average skin reactivity Comparative Example 7 12.5 Example 4 3.3 As shown in the results in Table 13, a group treated with Example 4 was found to have an excellent skin soothing effect by improving skin reactivity by 370% or more compared to Comparative Example 7.
[Industrial Applicability]
A placenta-mimic cosmetic composition according to the present invention can show excellent skin improvement effects such as whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing by adding hydroxyethylpiperazine ethane sulfonic acid (HEPES) to polydeoxyribonucleotide (PDRN), which is an active ingredient in the placenta, and adding peptides, amino acids, or vitamins to recombine.
Claims (13)
- [Claim 1]
A placenta-mimic composition comprising polydeoxyribonucleotide (PDRN), and hydroxyethylpiperazine ethane sulfonic acid (HEPES). - [Claim 21 The placenta-mimic composition of claim 1, further comprising one or more selected from the group consisting of peptides, amino acids, and vitamins.
- [Claim 3]
The placenta-mimic composition of claim 2, wherein one or more combinations selected from the group consisting of yeast polypeptides, oligopeptide-1, oligopeptide-2, copper tripeptide-1, and acetyl hexapeptide-8 are used as the peptides. - [Claim 4]
The placenta-mimic composition of claim 2, wherein one or more selected from the group consisting of arginine, tryptophan, threonine, lysine, valine, leucine, phenylalanine, histidine, isoleucine, tyrosine, potassium aspartate, sodium glutamate, glutamine, asparagine, proline, alanine, glycine, and serine are used as the amino acids. - [Claim 5]
The placenta-mimic composition of claim 2, wherein one or more selected from the group consisting of biotin, folic acid, cyanocobalamin, niacinamide, pantothenic acid, pyridoxine, riboflavin, and thiamine are used as the vitamins. - [Claim 6]
A cosmetic composition comprising the placenta-mimic composition of claim 1 or 2. - [Claim 7]
The cosmetic composition of claim 6, wherein the placenta-mimic cosmetic composition is for skin improvement. - [Claim 8]
The cosmetic composition of claim 7, wherein the skin improvement is whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing. - [Claim 9]
A cosmetic composition comprising polydeoxyribonucleotide (PDRN), hydroxyethylpiperazine ethane sulfonic acid (HEPES), peptides, amino acids, and vitamins. - [Claim 10]
The cosmetic composition of claim 9, wherein one or more combinations selected from the group consisting of yeast polypeptides, oligopeptide-1, oligopeptide-2, copper tripeptide-1, and acetyl hexapeptide-8 are used as the peptides. - [Claim 11]
The cosmetic composition of claim 9, wherein one or more selected from the group consisting of arginine, tryptophan, threonine, lysine, valine, leucine, phenylalanine, histidine, isoleucine, tyrosine, potassium aspartate, sodium glutamate, glutamine, asparagine, proline, alanine, glycine, and serine are used as the amino acids. - [Claim 121 The cosmetic composition of claim 9, wherein one or more selected from the group consisting of biotin, folic acid, cyanocobalamin, niacinamide, pantothenic acid, pyridoxine, riboflavin, and thiamine are used as the vitamins.
- [Claim 13]
A quasi-drug composition comprising the placenta-mimic composition of claim 1 or 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2021-0071411 | 2021-06-02 | ||
| KR20210071411 | 2021-06-02 | ||
| PCT/KR2022/007822 WO2022255809A1 (en) | 2021-06-02 | 2022-06-02 | Placenta-mimic cosmectic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3221138A1 true CA3221138A1 (en) | 2022-12-08 |
Family
ID=84324453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3221138A Pending CA3221138A1 (en) | 2021-06-02 | 2022-06-02 | Placenta-mimic cosmectic composition |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR20220163294A (en) |
| CN (1) | CN117396180A (en) |
| CA (1) | CA3221138A1 (en) |
| WO (1) | WO2022255809A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102657166B1 (en) * | 2024-01-02 | 2024-04-15 | 유엔케이코리아 주식회사 | Cosmetic composition for reducing wrinkle and improving elasticity containing PDRN and copper tripeptide-1 as active ingredient |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090002444A (en) | 2007-06-29 | 2009-01-09 | 동덕제약주식회사 | Human placenta hydrolysate-replaceable composition of porcine placenta hydrolysate and preparating method thereof |
| KR101289062B1 (en) | 2009-06-01 | 2013-07-22 | (주)차바이오앤디오스텍 | Cosmetic composition comprising growth factor and cytokine induced human placenta |
| KR20130024316A (en) * | 2011-08-31 | 2013-03-08 | (주)더페이스샵 | Cosmetic composition for improving skin condition comprising growth factor and cytokine induced human placenta |
| KR101414702B1 (en) * | 2011-09-09 | 2014-07-04 | 박수미 | Cosmetic composition for skin cell regeneration, anti-inflammation and skin calming effect, and preparing method thereof |
| JP6739472B2 (en) * | 2018-05-30 | 2020-08-12 | 株式会社粧薬研究所 | Agent containing horse placenta extract as active ingredient |
| KR20200072174A (en) * | 2018-12-12 | 2020-06-22 | 주식회사 씨티씨바이오 | Nanoliposome comprising PDRN and Centella asiatica extract and biodegradable microneedle containing the nanoliposome |
| KR102192587B1 (en) * | 2019-09-30 | 2020-12-17 | 대한뉴팜(주) | Excipients composition for preserving of stem cells |
-
2022
- 2022-06-02 KR KR1020220067532A patent/KR20220163294A/en unknown
- 2022-06-02 CN CN202280038749.8A patent/CN117396180A/en active Pending
- 2022-06-02 CA CA3221138A patent/CA3221138A1/en active Pending
- 2022-06-02 WO PCT/KR2022/007822 patent/WO2022255809A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220163294A (en) | 2022-12-09 |
| WO2022255809A1 (en) | 2022-12-08 |
| CN117396180A (en) | 2024-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2491910C2 (en) | Using natural active substances in cosmetic or therapeutic compositions | |
| US20150335692A1 (en) | Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles | |
| US20180371000A1 (en) | Process for obtaining an aqueous extract enriched with small rnas from a plant material and extracts resulting from the process | |
| CN110785161A (en) | Compositions and methods for improving the appearance of skin | |
| CN107308020B (en) | Stable polypeptide composition and application thereof | |
| JP2019509341A (en) | Cocoa bean peptide and sugar hydrolyzate, cosmetic composition containing it, and cosmetic use thereof | |
| KR20160063394A (en) | Cosmetic or dermatological use of an extract of hamamelis virginiana | |
| JP2016510016A (en) | Cosmetic composition containing brown algae extract, yeast extract and ascorbic acid | |
| CN102227208A (en) | Drug or dermatological composition containing avocado peptide extract for treating and preventing pruritus | |
| KR102450968B1 (en) | Lupin peptide extracts and skin firmness | |
| KR20150135433A (en) | Cosmetic or dermatological use of a polygonum bistorta extract | |
| CA3221138A1 (en) | Placenta-mimic cosmectic composition | |
| KR20030086270A (en) | Method for suppressing reduction of elasticity of skin | |
| US20240024224A1 (en) | Anti-aging and antioxidant cosmetic composition containing broccoli exosomes as active ingredient and functional cosmetics comprising same | |
| KR102063686B1 (en) | Skin external composition containing extract of soybean root | |
| KR20230074492A (en) | Novel uses of peptides to improve skin and/or mucous membrane comfort and/or improve the appearance of dandruff | |
| KR20070082635A (en) | Antiaging composition for external skin application containing the needles of red pine | |
| KR102281606B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex | |
| KR20160146406A (en) | Cosmetic composition comprising sea cucumber steaming juice or a fraction thereof as functional component | |
| US10596095B2 (en) | Method for moisturizing skin using P-113 peptide | |
| JP2024521213A (en) | Shihe car imitation cosmetic composition | |
| TWI788019B (en) | Use of chamaemelum nobile extract for manufacturing skincare composition | |
| KR102667277B1 (en) | Extract of Moringa peregrina seed cake, process for its preparation and use thereof in cosmetic or nutricosmetic compositions | |
| US20240130948A1 (en) | Compositions and methods for improving the appearance of the skin | |
| KR20130116641A (en) | Composition of skin external application containing polysaccharides, and the method for preparing thereof |